Oricell Therapeutics closes USD 110m pre-IPO financing for solid tumor CAR-T development

Oricell Therapeutics Holdings Ltd, a clinical-stage biotechnology company headquartered in Shanghai, China, [announced](https://www.prnewswire.com/news-releases/oricell-therapeutics-closes-110-million-pre-ipo-financing-to-accelerate-global-development-of-solid-tumor-car-t-therapies-302738393.html) the cumulative closing of a pre-IPO financing round exceeding USD 110 million on April 9, 2026. The company did not disclose the exchange, ticker symbol, or formal IPO offering terms in connection with the announcement. The filing did not disclose the number of shares offered, a price range, gross proceeds from a public offering, or the identity of underwriters. No formal IPO prospectus has been publicly filed with the HKEX or SEC as of the announcement date. Ownership structure and use of proceeds were not disclosed. Oricell Therapeutics is developing CAR-T cell therapies targeting solid tumors, with its lead asset [Ori-C101](https://app.allsci.com/drugs/ASC-DR-0000000032761-1.0-1772718717) being a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma. The US FDA has granted Ori-C101 both Orphan Drug Designation and Fast Track Designation, and the asset has received IND clearance from both the US FDA and China's NMPA. The company's pipeline also includes OriCAR-017, a GPRC5D-targeted CAR-T therapy for relapsed or refractory multiple myeloma, which holds [FDA IND clearance](https://app.allsci.com/news/ASC-NR-0000000125190-1.0-1769544022?query=OriCAR-017). In a Phase I study of Ori-C101 in ten GPC3-positive advanced HCC patients, the company stated a disease control rate of 90% and a partial response rate of 60% per RECIST 1.1 criteria, with the safety profile described as favorable; results were presented at [ASCO 2025.](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4084) For OriCAR-017, the filing states that the Phase I POLARIS trial in ten relapsed or refractory multiple myeloma patients produced a [100% overall response rate](https://app.allsci.com/article/ASC-PB-0000200739847-1.0-1731074082) at both initial assessment and 24-month follow-up, with a stringent complete response rate of 80% and 100% MRD negativity at day 28, as published in The Lancet Haematology. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/oricell-therapeutics-financing-closes-usd-110m)